カテゴリ： GlobalData, アメリカ, 企業調査

Albireo Pharma Inc (ALBO)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9961
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：69
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe medical conditions for which there is high unmet need. The company’s lead product candidate, A4250 is a novel, minimally absorbed, orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor. The product is in a Phase III clinical trial for progressive familial intrahepatic cholestasis (PFIC), a rare, life-threatening genetic disorder affecting young children and potentially other orphan pediatric liver diseases. Albireo is located in Boston, Massachusetts, the US.

Albireo Pharma Inc (ALBO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Albireo to Raise USD10 Million in Venture Financing 12
Partnerships 13
Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13
Merger 14
Biodel and Albireo Merges 14
Licensing Agreements 16
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16
Biodel Terminates Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17
Equity Offering 18
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 18
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 19
Albireo Pharma Raises USD52 Million in Public Offering of Shares 21
Biodel Raises USD34.5 Million in Public Offering of Shares 23
Biodel to Raise up to USD15 Million in Private Placement of Shares 25
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 27
Biodel Completes Public Offering Of Shares For US$20.5 Million 28
Biodel Completes Private Placement Of Units For US$18.5 Million 29
Asset Transactions 30
Albireo Pharma Enters into Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat 30
Albireo Pharma Inc – Key Competitors 31
Albireo Pharma Inc – Key Employees 32
Albireo Pharma Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 07, 2018: Albireo reports second quarter 2018 financial results 34
May 17, 2018: Albireo Provides First Quarter 2018 Business Update 36
Mar 15, 2018: Albireo Reports Fourth Quarter and Year-End 2017 Financial Results 37
Nov 14, 2017: Albireo Reports Third Quarter 2017 Financial Results 39
Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 41
May 10, 2017: Albireo Reports First Quarter 2017 Financial Results 43
Mar 14, 2017: Albireo Reports 2016 Financial Results 45
Corporate Communications 47
Oct 10, 2018: Albireo appoints Simon Harford as chief financial officer and treasurer 47
Jul 25, 2018: Albireo appoints Patrick Horn as Chief Medical Officer 48
Jun 08, 2018: Albireo Names Anne Klibanski and Stephanie Okey As Board Directors 49
Sep 28, 2017: Albireo Elects Roger Jeffs to Board of Directors 50
Product News 51
05/28/2018: PIII Clinical Study Data on Chronic Constipation Treatment “GOOFICE 5mg Tablet” Will Be Presented at DDW2018 51
04/19/2018: World’s First Bile Acid Transporter Inhibitor GOOFICE 5mg Tablet Launched in Japan 52
04/19/2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting 53
01/19/2018: New drug approval of bile acid transporter inhibitor “GOOFICE 5mg Tablet ”for chronic constipation was obtained in Japan 54
Product Approvals 55
Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan 55
Clinical Trials 56
Jul 09, 2018: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment GOOFICE 5mg Tablet Published in The Lancet Gastroenterology & Hepatology 56
Jun 12, 2018: FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher 57
May 16, 2018: Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250 58
Apr 14, 2018: Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The International Liver Congress 2018 59
Mar 28, 2018: Albireo to Present Clinical Data on A4250 at The International Liver Congress 2018 60
Oct 20, 2017: Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting 2017 61
Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017 62
Sep 26, 2017: EMA’s Paediatric Committee Agrees to Albireo’s A4250 Pediatric Investigation Plan 63
May 18, 2017: Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC 64
Apr 27, 2017: Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017 66
Apr 22, 2017: Promising Pediatric Data for Albireo’s A4250 to be Presented at The International Liver Congress 2017 67
Apr 05, 2017: EASL Selects Albireo’s A4250 Data for Late Breaker Presentation 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Albireo Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Albireo to Raise USD10 Million in Venture Financing 12
Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13
Biodel and Albireo Merges 14
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16
Biodel Terminates Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 18
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 19
Albireo Pharma Raises USD52 Million in Public Offering of Shares 21
Biodel Raises USD34.5 Million in Public Offering of Shares 23
Biodel to Raise up to USD15 Million in Private Placement of Shares 25
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 27
Biodel Completes Public Offering Of Shares For US$20.5 Million 28
Biodel Completes Private Placement Of Units For US$18.5 Million 29
Albireo Pharma Enters into Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat 30
Albireo Pharma Inc, Key Competitors 31
Albireo Pharma Inc, Key Employees 32
Albireo Pharma Inc, Other Locations 33
Albireo Pharma Inc, Subsidiaries 33

List of Figures
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Albireo Pharma Inc (ALBO)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Nutritional Resources Inc：企業の戦略・SWOT・財務情報
    Nutritional Resources Inc - Strategy, SWOT and Corporate Finance Report Summary Nutritional Resources Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Aeras Global TB Vaccine Foundation Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Aeras Global TB Vaccine Foundation Inc (Aeras) is a non-profit biotech organization that develops tuberculosis (TB) vaccines. The organization offers TB vaccine candidates, preclinical candidates and vaccine candidates. Its services include portfolio management, preclinical research, clinica …
  • Covis Pharma Sarl-製薬・医療分野：企業M&A・提携分析
    Summary Covis Pharma Sarl (Covis Pharma), a subsidiary of Concordia International Corp is a specialty pharmaceutical company that develops and markets drugs for the treatment of life-threatening conditions and chronic illnesses. The company develops products for central nervous system and rheumatic …
  • AMC Entertainment Holdings, Inc.：企業のM&A・事業提携・投資動向
    AMC Entertainment Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AMC Entertainment Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Carna Biosciences Inc (4572)：企業の財務・戦略的SWOT分析
    Summary Carna Biosciences Inc (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive- …
  • Ferrovial, S.A. (FER)：企業の財務・戦略的SWOT分析
    Ferrovial, S.A. (FER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Noven Pharmaceuticals, Inc.：企業の戦略・SWOT・財務情報
    Noven Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Noven Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • SymBio Pharmaceuticals Ltd (4582)：企業の財務・戦略的SWOT分析
    Summary SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. Its pipeline product portfolio includes Treakisym (SyB L-0501), an anti-cancer agent used for the treatment of non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chr …
  • BrightPath Early Learning Inc.：企業の戦略的SWOT分析
    BrightPath Early Learning Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • University of Southern California-製薬・医療分野：企業M&A・提携分析
    Summary University of Southern California (USC) is a medical education and research institution that provides educational courses in the field of arts and sciences, accounting, architecture, art and design, arts and tech, business, cinematic arts, communication, journalism and dance. The institute a …
  • Edwards Lifesciences Corp (EW)：企業の財務・戦略的SWOT分析
    Edwards Lifesciences Corp (EW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Aurora Health Care Inc：企業の戦略的SWOT分析
    Aurora Health Care Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Pick N Pay Stores Limited：企業の戦略・SWOT・財務分析
    Pick N Pay Stores Limited - Strategy, SWOT and Corporate Finance Report Summary Pick N Pay Stores Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Anagenesis Biotechnologies：製薬・医療：M&Aディール及び事業提携情報
    Summary Anagenesis Biotechnologies is a pharmaceutical solutions provider that offers treatment for muscle degenerative diseases. The company provides cell therapy genetics and pharmacological drugs for genetic and age related diseases. It also carries out cell-based technologies to provide solution …
  • Mereo Biopharma Group Plc (MPH)：製薬・医療：M&Aディール及び事業提携情報
    Summary Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone sy …
  • Sacgasco Ltd (SGC)：企業の財務・戦略的SWOT分析
    Summary Sacgasco Ltd (Sacgasco) formerly Australian Oil Company Ltd, is an energy company that provides conventional oil and gas exploration, development and production across Australia. The company develops and produces clean natural gas in the Sacramento Basin, onshore California. It explores Sacr …
  • Matisa Materiel Industriel S.A.：企業の戦略・SWOT・財務分析
    Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report Summary Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Medicago Inc：企業のM&A・事業提携・投資動向
    Medicago Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medicago Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Koninklijke Ten Cate NV：企業の戦略的SWOT分析
    Koninklijke Ten Cate NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • CSX Corp (CSX)：企業の財務・戦略的SWOT分析
    CSX Corp (CSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆